For comparison, we evaluated the TS mRNA status and pemetrexed‐based treatment efficacy from 170 NSCLC patients with anaplastic lymphoma kinase (ALK) translocation (n = 46), EGFR mutation (n = 50), KRAS mutation (n = 32), and wild‐type of EGFR/ALK/ROS1/KRAS (n = 42). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.